DK2087002T3 - Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat - Google Patents

Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat

Info

Publication number
DK2087002T3
DK2087002T3 DK07871262.7T DK07871262T DK2087002T3 DK 2087002 T3 DK2087002 T3 DK 2087002T3 DK 07871262 T DK07871262 T DK 07871262T DK 2087002 T3 DK2087002 T3 DK 2087002T3
Authority
DK
Denmark
Prior art keywords
phosphate
compositions
methods
binding sphingosine
sphingosine
Prior art date
Application number
DK07871262.7T
Other languages
Danish (da)
English (en)
Inventor
Roger A Sabbadini
William A Garland
Genevieve Hansen
Steven Tarran Jones
David Gareth Williams
Original Assignee
Lpath Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lpath Inc filed Critical Lpath Inc
Application granted granted Critical
Publication of DK2087002T3 publication Critical patent/DK2087002T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07871262.7T 2006-10-27 2007-10-26 Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat DK2087002T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85497106P 2006-10-27 2006-10-27
PCT/US2007/082647 WO2008070344A2 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate

Publications (1)

Publication Number Publication Date
DK2087002T3 true DK2087002T3 (da) 2014-10-27

Family

ID=39492938

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07871262.7T DK2087002T3 (da) 2006-10-27 2007-10-26 Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat

Country Status (18)

Country Link
US (6) US7829674B2 (enExample)
EP (1) EP2087002B1 (enExample)
JP (2) JP5795833B2 (enExample)
KR (1) KR101581279B1 (enExample)
CN (2) CN101679506B (enExample)
AU (1) AU2007329759B2 (enExample)
BR (1) BRPI0718118A2 (enExample)
CA (1) CA2667574A1 (enExample)
DK (1) DK2087002T3 (enExample)
ES (1) ES2524059T3 (enExample)
IL (1) IL198379A (enExample)
MX (1) MX2009004532A (enExample)
PL (1) PL2087002T3 (enExample)
PT (1) PT2087002E (enExample)
RU (1) RU2460541C2 (enExample)
SI (1) SI2087002T1 (enExample)
WO (1) WO2008070344A2 (enExample)
ZA (1) ZA200902860B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186339A1 (en) * 2006-10-27 2014-07-03 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
WO2009108633A2 (en) * 2008-02-25 2009-09-03 Expression Drug Designs, Llc. Sphingosine 1-phosphate antagonism
US8212010B2 (en) 2008-02-25 2012-07-03 Expression Drug Designs, Llc Sphingosine 1-phosphate antagonism
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
EP2374001A4 (en) * 2008-12-05 2013-03-13 Lpath Inc ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES
US20100292443A1 (en) * 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
WO2010127069A1 (en) * 2009-04-29 2010-11-04 Schering Corporation Antibody purification
LT2462158T (lt) 2009-08-06 2018-03-26 F. Hoffmann-La Roche Ag Viruso pašalinimo pagerinimo būdas, atliekant baltymų gryninimą
GB2476681B (en) * 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
WO2011109650A1 (en) * 2010-03-03 2011-09-09 The Board Of Trustees Of The University Of Illinois Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists
US9102718B2 (en) * 2010-04-30 2015-08-11 Lpath, Inc. Anti-S1P antibody treatment of patients with ocular disease
JP2013543479A (ja) * 2010-06-06 2013-12-05 エルパス・インコーポレイテッド 抗ｓ１ｐ抗体およびスフィンゴ脂質経路阻害剤の組み合わせ
WO2012015758A2 (en) 2010-07-30 2012-02-02 Saint Louis University Methods of treating pain
EP2646047A2 (en) * 2010-12-01 2013-10-09 Universität Zürich Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
JP5766958B2 (ja) * 2011-01-21 2015-08-19 オリンパス株式会社 顕微鏡システム、情報処理装置、及び情報処理プログラム
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
JP2014524581A (ja) 2011-08-19 2014-09-22 マルバーン インストゥルメンツ リミテッド 微粒子のデュアルモード特徴付け
MX354303B (es) 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
BR112014030843A2 (pt) 2012-07-04 2019-10-15 Hoffmann La Roche anticorpo anti-teofilina, formulação farmacêutica e uso do anticorpo
CN107973856B (zh) 2012-07-04 2021-11-23 弗·哈夫曼-拉罗切有限公司 共价连接的抗原-抗体缀合物
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP2787006B1 (en) 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 antibody which binding is Ca2+ dependent
JP6521464B2 (ja) 2014-01-03 2019-05-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合で連結されたポリペプチド毒素−抗体コンジュゲート
RU2693438C2 (ru) 2014-01-03 2019-07-02 Ф. Хоффманн-Ля Рош Аг Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
BR112016012666A2 (pt) 2014-01-03 2017-09-26 Hoffmann La Roche conjugado, anticorpos, formulação farmacêutica e usos de conjugado
JP6654581B2 (ja) 2014-06-26 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｂｒｄｕ抗体および使用方法
JP6716557B2 (ja) * 2014-11-06 2020-07-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 浸出物および／または抽出物の除去のための活性炭
US9754383B1 (en) * 2014-12-22 2017-09-05 Flagship Biosciences, Inc. Automated methods for assessment of celiac disease
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
MX2018015452A (es) 2016-12-15 2020-02-10 Soc Des Produits Nestle S A Star Composiciones y metodos que modulan fosforo o las enzimas en un aminal de compañia.
WO2018191747A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension
AU2018251209B2 (en) 2017-04-14 2021-11-04 Arizona Board Of Regents On Behalf Of The University Of Arizonia Compositions and methods for treating pulmonary fibrosis

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1073471B (de) 1958-09-02 1960-01-21 Chemische Werke Hüls Aktiengesellschaft, Marl (Kr. Recklinghausen) Verfahren zur Herstellung von Azelainsäure
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1573212A (en) * 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
SE455445B (sv) 1984-08-28 1988-07-11 Pharmacia Ab Antikroppar mot sialosyllaktotetraos (iv?723neuaclcose?714) och antikroppens resp antigenets anvendning vid tumordiagnostik
EP0173648A3 (en) 1984-08-30 1988-04-27 Ciba-Geigy Ag New monoclonal antibodies to glycoconjugates, processes for their production, and applications
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4937232A (en) * 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
DE3741056A1 (de) * 1987-12-04 1989-08-24 Behringwerke Ag Manumycin-derivate, verfahren zu ihrer herstellung und ihre verwendung
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5248824A (en) * 1990-12-31 1993-09-28 The Biomembrane Institute Method of preparing N,N,N-trimethylsphingosine
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US5137919A (en) * 1990-12-31 1992-08-11 Biomembrane Institute Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
US5677288A (en) 1991-05-15 1997-10-14 Cypros Pharmaceutical Corporation Use of aminoglycosides to protect against excitotoxic neuron damage
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
CA2128862C (en) 1992-02-11 2008-05-20 Jonathan G. Seidman Homogenotization of gene-targeting events
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5260288A (en) * 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
US5369030A (en) 1992-09-11 1994-11-29 Duke University Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5444087A (en) 1993-10-19 1995-08-22 Bristol-Myers Squibb Company Manumycin compounds
JPH09505058A (ja) * 1993-11-15 1997-05-20 ベイカー・メディカル・リサーチ・インスティテュート 心機能不全の治療方法およびそのために有用な医薬組成物
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
WO1995021175A1 (en) 1994-02-02 1995-08-10 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use therof
US5430169A (en) 1994-02-14 1995-07-04 The United States Of America Represented By The Department Of Health And Human Services Method for preparation of sphingoid bases
US5585476A (en) 1994-02-15 1996-12-17 Maclennan; Alexander J. Molecular cloning and expression of G-protein coupled receptors
US5627171A (en) 1994-04-11 1997-05-06 Oncomembrane, Inc. Sphingosine-1-phosphate/trimethylsphingosine composition
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5667337A (en) 1995-09-15 1997-09-16 Lazes; Richard J. Rotating containment and repelling boom and method for confining a material floatable on a liquid surface
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) * 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
JPH09110722A (ja) 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
DE19621038A1 (de) * 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
CA2260768C (en) 1996-07-19 2008-06-17 Takara Shuzo Co., Ltd. Methods for producing sphingolipids and sphingolipid derivatives
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6140060A (en) * 1996-12-12 2000-10-31 Chun; Jerold J. M. Cloned lysophosphatidic acid receptors
US5919687A (en) * 1996-12-24 1999-07-06 John Hopkins University Recombinant N-SMases and nucleic acids encoding same
AU6310198A (en) 1997-03-12 1998-09-29 Takara Shuzo Co., Ltd. Sphingosine analogues
US6210976B1 (en) * 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
CA2300977A1 (en) 1997-08-11 1999-02-18 Wilhelm Stoffel Neutral sphingomyelinase
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
US6649362B2 (en) * 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
DE69835223T2 (de) 1997-09-11 2007-05-31 Takara Bio Inc., Otsu Sphingosinderivate und medizinische zubereitung
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6057126A (en) * 1997-12-24 2000-05-02 Allelix Biopharmaceuticals, Inc. Mammalian EDG-5 receptor homologs
WO1999038983A1 (en) 1998-01-29 1999-08-05 Smithkline Beecham Plc Novel sphingosine-1 phosphate lyase
WO1999041266A1 (en) 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
PT1055682E (pt) 1998-02-16 2004-12-31 Kitasato Inst Nova substancia kf-1040 e processo para a producao da mesma
WO1999046277A1 (en) 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
EP1071458A4 (en) 1998-03-13 2005-02-16 Dana Farber Cancer Inst Inc HUMANIZED ANTIBODIES AND CORRESPONDING USES THEREOF
US6130067A (en) * 1998-05-20 2000-10-10 Smithkline Beecham Corporation Human EDG3sb gene
WO1999061581A2 (en) 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
DE19828850A1 (de) 1998-06-27 1999-12-30 Gvs Ges Fuer Erwerb Und Verwer Sphingolipid-Desaturase
BR9912501A (pt) * 1998-06-29 2001-05-02 Los Angeles Childrens Hospital Tratamento de distúrbios hiperproliferativos
DE19847149A1 (de) 1998-10-13 2000-04-20 Max Planck Gesellschaft Pseudo-Ceramide
CN1214043C (zh) 1998-12-01 2005-08-10 蛋白质设计实验室股份有限公司 抗γ－干扰素的人化抗体
ATE330631T1 (de) 1999-01-05 2006-07-15 Univ Southern Australia Antikörperfragmente zur lokalen behandlung von augenerkrankungen
WO2000052173A2 (en) 1999-03-02 2000-09-08 Nps Allelix Corp. Cloned human sphingosine kinase homologues
US6812335B1 (en) 1999-03-23 2004-11-02 The Regents Of The University Of California Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
WO2000058491A1 (en) 1999-03-25 2000-10-05 The Kitasato Institute Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same
ATE362526T1 (de) 1999-03-26 2007-06-15 Takara Bio Inc Ceramidasegen
US7820718B1 (en) 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
JP2000293181A (ja) 1999-04-12 2000-10-20 Daiichikosho Co Ltd 歌詞画像描出機能に特徴を有するカラオケ装置
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
NZ515132A (en) 1999-05-13 2005-01-28 Johnson & Johnson Pharm Res Sphingosine kinase enzyme
DE19924148A1 (de) 1999-05-26 2000-12-07 Univ Heidelberg Sphingomyelinasehemmer
WO2001004139A2 (en) 1999-07-13 2001-01-18 Smithkline Beecham Corporation Human axor29 receptor
IT1307786B1 (it) 1999-07-22 2001-11-19 Bracco Spa Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
CA2389127A1 (en) 1999-10-28 2001-05-03 Warner-Lambert Company Human sphingosine kinase gene
AU1548101A (en) 1999-11-24 2001-06-04 Sagami Chemical Research Center Sphingosine derivatives
AU2001233086A1 (en) 2000-01-28 2001-08-07 Musc Foundation For Research Development Ceramidase compositions and methods based thereon
AU2001238048A1 (en) 2000-02-07 2001-08-14 Merck And Co., Inc. Mammalian sphingosine-1-phosphate phosphatase
US6306911B1 (en) * 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
CA2402148A1 (en) 2000-02-14 2001-08-23 Curagen Corporation Novel sphingosine kinases
JP2001261575A (ja) * 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
AU2001247755A1 (en) 2000-03-23 2001-10-03 Millennium Pharmaceuticals, Inc. High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi
AU2001255199A1 (en) 2000-03-28 2001-10-08 The Liposome Company, Inc. Ceramide derivatives and method of use
AU2001255477A1 (en) 2000-04-19 2001-11-07 The Trustees Of Columbia University In The City Of New York Detection and treatment of atherosclerosis based on plasma sphingomyelin concentration
AUPQ744700A0 (en) 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US6571638B2 (en) 2000-06-30 2003-06-03 Sawtek, Inc. Surface-acoustic-wave pressure sensor and associated methods
US20030125533A1 (en) * 2000-10-06 2003-07-03 Sophia Kossida Regulation of human sphingosine kinase-like protein
ES2523856T3 (es) 2000-12-22 2014-12-02 Lpath, Inc. Anticuerpos de esfingosina-1-fosfato para el tratamiento de enfermedades asociadas con elevadas concentraciones de esfingolípidos
US20020150582A1 (en) * 2001-02-08 2002-10-17 Friedrichs Gregory S. Method of treating or inhibiting cellular injury or cell death
US7674580B2 (en) * 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7611851B2 (en) * 2004-07-27 2009-11-03 Merck & Co., Inc. Canis sphingosine 1-phosphate receptor isoform 1
DK1812797T3 (da) * 2004-10-28 2013-05-21 Lpath Inc Sammensætninger og fremgangsmåder til behandling og forebyggelse af hyperproliferative sygdomme
WO2006104989A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
US20080213274A1 (en) 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions

Also Published As

Publication number Publication date
US20100003242A1 (en) 2010-01-07
JP2010515427A (ja) 2010-05-13
US20090130100A1 (en) 2009-05-21
AU2007329759A1 (en) 2008-06-12
EP2087002B1 (en) 2014-09-24
US20090148443A1 (en) 2009-06-11
US7829674B2 (en) 2010-11-09
PL2087002T3 (pl) 2015-02-27
US8222373B2 (en) 2012-07-17
IL198379A (en) 2015-04-30
US20090130099A1 (en) 2009-05-21
CA2667574A1 (en) 2008-06-12
BRPI0718118A2 (pt) 2017-05-30
JP5795833B2 (ja) 2015-10-14
CN104650225B (zh) 2019-10-01
MX2009004532A (es) 2009-09-04
JP6053834B2 (ja) 2016-12-27
CN101679506B (zh) 2015-02-25
KR101581279B1 (ko) 2015-12-31
PT2087002E (pt) 2014-11-26
ZA200902860B (en) 2010-07-28
ES2524059T3 (es) 2014-12-03
CN101679506A (zh) 2010-03-24
KR20100043137A (ko) 2010-04-28
RU2009120052A (ru) 2010-12-10
US8025877B2 (en) 2011-09-27
EP2087002A4 (en) 2010-06-30
WO2008070344A3 (en) 2008-11-20
EP2087002A2 (en) 2009-08-12
US8026342B2 (en) 2011-09-27
JP2015134760A (ja) 2015-07-27
CN104650225A (zh) 2015-05-27
WO2008070344A2 (en) 2008-06-12
AU2007329759B2 (en) 2013-05-30
US8067549B2 (en) 2011-11-29
US20090010922A1 (en) 2009-01-08
US7956173B2 (en) 2011-06-07
WO2008070344A9 (en) 2008-08-28
SI2087002T1 (sl) 2014-11-28
US20090137037A1 (en) 2009-05-28
RU2460541C2 (ru) 2012-09-10
IL198379A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
NO20201120A1 (no) Bindingsvirkninger
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
DK2253644T3 (da) Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK2041071T3 (da) Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
DK3207941T3 (da) Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater
DK2099489T3 (da) Sammensætninger og fremgangsmåder til behandling af en neoplasme
DK2245064T3 (da) BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
DK3263589T5 (da) Peptidsekvenser og sammensætninger
DK2102398T3 (da) Fremgangsmåde til fremstilling af en ankelsok og ankelsok opnået derved
DK2054711T3 (da) Fremgangsmåde til fremstilling af mikroarrays
BRPI0716325A2 (pt) Composição antimicrobianas
DK2069312T3 (da) Pyridazinonderivater
DK3263112T3 (da) Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
DK2089047T3 (da) Sammensætninger og fremgangsmåder til beskyttelse og regenerering af hjerte-væv
FR2899479B1 (fr) Composition cicatrisante
DK1912476T3 (da) Fremgangsmåde til træning af høreevne
DK2187967T3 (da) Fremgangsmåde og sammensætninger til behandling af cancere
DK2320739T3 (da) Farmaceutiske sammensætninger og fremgangsmåder til stabilisering af disse
DK1986508T3 (da) Fremgangsmåder og sammensætninger til behandling af felin hyperthyroidisme
DK2262525T3 (da) Apoaequorin-holdige sammensætninger og fremgangsmåder til anvendelse af de samme